Currently, there are 42.46M common shares owned by the public and among those 41.30M shares have been available to trade.
The company’s stock has a 5-day price change of -1.68% and -41.63% over the past three months. BTAI shares are trading -9.07% year to date (YTD), with the 12-month market performance down to -87.68% lower. It has a 12-month low price of $0.30 and touched a high of $4.17 over the same period. BTAI has an average intraday trading volume of 968.77K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -11.56%, -21.95%, and -67.42% respectively.
Institutional ownership of BioXcel Therapeutics Inc (NASDAQ: BTAI) shares accounts for 17.36% of the company’s 42.46M shares outstanding.
It has a market capitalization of $16.87M and a beta (3y monthly) value of 0.00. The earnings-per-share (ttm) stands at -$2.15. Price movements for the stock have been influenced by the stock’s volatility, which stands at 16.25% over the week and 16.34% over the month.
Analysts forecast that BioXcel Therapeutics Inc (BTAI) will achieve an EPS of -0.37 for the current quarter, -0.33 for the next quarter and -1.16 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.42 while analysts give the company a high EPS estimate of -0.42. Comparatively, EPS for the current quarter was -0.76 a year ago. Earnings per share for the fiscal year are expected to increase by 72.28%, and 21.85% over the next financial year.
Looking at the support for the BTAI, a number of firms have released research notes about the stock. UBS stated their Neutral rating for the stock in a research note on February 21, 2024, with the firm’s price target at $9-$4. Mizuho coverage for the BioXcel Therapeutics Inc (BTAI) stock in a research note released on August 15, 2023 offered a Neutral rating with a price target of $4. Guggenheim was of a view on July 17, 2023 that the stock is Neutral, while Jefferies gave the stock Hold rating on March 10, 2023, issuing a price target of $20- $22. Goldman on their part issued Neutral rating on December 01, 2022.
